NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
BackgroundParkinson's disease (PD) involves motor impairment and neurochemical changes, necessitating neuroprotective agents to enhance nursing care outcomes.MethodsIron oxide nanoparticles (IONPs) were biosynthesized via green chemistry and characterized by TEM, UV-Vis, photoluminescence, XRD, and VSM. Antioxidant activity used DPPH assay; biocompatibility involved MTT and hemolysis assays. Efficacy was tested in an MPTP-induced mouse model of PD, assessing motor function, antioxidant capacity, and dopaminergic neuron protection.ResultsIONPs exhibited spherical morphology (39.0 ± 11.3 nm), zeta potential of -13 mV, and saturation magnetization of 42.32 emu/g. They showed concentration-dependent DPPH scavenging and no significant cytotoxicity or hemolysis up to 10 µg/mL. In vitro, IONPs improved motor performance, boosted antioxidants, and reduced apoptosis in dopamine neurons.ConclusionBiosynthesized IONPs offer promise as a complementary PD therapy by mitigating motor deficits and neurochemical damage.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.